Inactive Instrument

Titan Pharmaceuticals, Inc. Share Price Nasdaq

Equities

US8883143096

Pharmaceuticals

Sales 2022 557K 46.48M Sales 2023 184K 15.35M Capitalization 6.21M 519M
Net income 2022 -10M -834M Net income 2023 -5M -417M EV / Sales 2022 15.6 x
Net cash position 2022 2.75M 229M Net cash position 2023 6.2M 517M EV / Sales 2023 0.11 x
P/E ratio 2022
-1.03 x
P/E ratio 2023
-1.11 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 54.53%
More Fundamentals * Assessed data
Dynamic Chart
Members of the board TitleAgeSince
Director/Board Member 53 15/22/15
Chief Executive Officer 42 12/23/12
Director/Board Member - 12/23/12
More insiders
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
More about the company